Uncategorized
PharmaScroll
July 25, 2023
A US pharmaceutical company asked for help identifying Key Opinion Leaders specializing in Alzheimer's disease for Phase 3 drug development.
Background
Alzheimer's disease is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and behavioral changes. Expert guidance and leadership from industry Key Opinion Leaders (KOLs) possessing extensive knowledge, clinical expertise, and significant impact is crucial for advancing research, promoting awareness, and shaping treatment strategies for Alzheimer's disease.
Our goal was to identify the most influential KOLs in Alzheimer's disease by analyzing research publications, clinical trial contributions, conference presentations, and social media influence. This case study outlines identifying these KOLs and highlights the importance of collaborating with experts with extensive clinical experience and research accomplishments during Phase 3 clinical studies.
Methodology
The project involved a combination of data analysis from the TreasureTell database and secondary desk research, data collection, and data analysis.
- Research Publications: The number and impact of research publications related to Alzheimer's disease were considered to assess the expertise and contributions of potential KOLs.
- Clinical Trial Involvement: : KOLs' participation, leadership roles, and contributions in Phase 3 clinical trials for Alzheimer's disease were analyzed.
- Leadership Roles: Leadership positions in scientific organizations, editorial boards, and guideline committees related to Alzheimer's disease were considered indicators of influence and expertise.
- Recommendations From Experts: Recommendations provided by experts in the field were considered to identify potential KOLs for the Phase 3 study.
Criteria for Evaluation
The following criteria were considered during the evaluation process:
- Number and impact of research publications in the field of Alzheimer's disease.
- Leadership roles and involvement in clinical trials.
- Number of conference presentations and their significance
- Online presence, engagement, and influence on social media platforms.
- Collaborations with other renowned experts in Alzheimer's disease research.
Results and Analysis
Based on the data collected and evaluation criteria, a list of potential KOLs for the Phase 3 study in Alzheimer's disease was generated. Each potential KOL's expertise, previous involvement in Phase 3 studies, publication record, leadership roles, and recommendations from experts were analyzed. The strengths and contributions of each KOL (Key Opinion Leaders) were assessed to determine their suitability for the Phase 3 study.
The identified potential KOLs were discussed in terms of their expertise, previous involvement in Phase 3 studies, leadership roles, and recommendations from experts. Their potential contributions to the trial design, patient recruitment strategies, data analysis, and interpretation were considered. The discussion highlighted the unique strengths and expertise of each KOL and how they align with the goals of the Phase 3 study.
Through extensive research and analysis, we have identified the below top five KOLs in Alzheimer's disease.
- Ronald C. Petersen, MD, PhD
Director, Mayo Clinic, Alzheimer's Disease Research Center, and the Mayo Clinic Study of Aging
- Bradley Theodore Hyman, MD, PhD
Director, Massachusetts General Hospital, MA, US
- John Carl Morris, MD
Professor, Washington University School of Medicine, St Louis, MO, US
- Paul Aisen, MD
Director, Mayo Clinic, Alzheimer's Disease Research Center, and the Mayo Clinic Study of Aging
- Maria Carrillo, PhD
Chief Science Officer, Alzheimer's Association
PharmaScroll’s KOL database, TreasureTell provides insights into KOLs’ opinions on drug developments, clinical trials, and other healthcare industry advancements. TreasureTell also provides insights on KOLs’ clinical trial involvements, publications, latest engagements, and much more.
Request a demo: enquiry@pharmascroll.com